Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 283

1.

Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.

Chen JF, Chern Y.

Handb Exp Pharmacol. 2011;(200):267-310. doi: 10.1007/978-3-642-13443-2_10. Review.

PMID:
20859800
2.

Adenosine receptors and neurological disease: neuroprotection and neurodegeneration.

Stone TW, Ceruti S, Abbracchio MP.

Handb Exp Pharmacol. 2009;(193):535-87. doi: 10.1007/978-3-540-89615-9_17. Review.

PMID:
19639293
3.

Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.

Kalda A, Yu L, Oztas E, Chen JF.

J Neurol Sci. 2006 Oct 25;248(1-2):9-15. Epub 2006 Jun 27. Review.

PMID:
16806272
4.

The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.

Chen JF.

Drug News Perspect. 2003 Nov;16(9):597-604. Review.

PMID:
14702141
5.

An update on pharmacological approaches to neurodegenerative diseases.

Scatena R, Martorana GE, Bottoni P, Botta G, Pastore P, Giardina B.

Expert Opin Investig Drugs. 2007 Jan;16(1):59-72. Review.

PMID:
17155854
6.

Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation.

Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, Geiger J, Lopes LV, de Mendonça A.

Prog Neurobiol. 2007 Dec;83(5):310-31. Epub 2007 Sep 29. Review.

PMID:
18023959
7.

New therapeutic strategy for Parkinson's and Alzheimer's disease.

Esposito E, Cuzzocrea S.

Curr Med Chem. 2010;17(25):2764-74. Review.

PMID:
20586718
8.

Adenosine A2A receptors and neuroprotection.

Ongini E, Adami M, Ferri C, Bertorelli R.

Ann N Y Acad Sci. 1997 Oct 15;825:30-48. Review.

PMID:
9369973
9.

Xanthine derivatives in the heart: blessed or cursed?

Szentmiklósi AJ, Cseppentō A, Gesztelyi R, Zsuga J, Körtvély A, Harmati G, Nánási PP.

Curr Med Chem. 2011;18(24):3695-706. Review.

PMID:
21774759
10.

Adenosine and related drugs in brain diseases: present and future in clinical trials.

Lopes LV, Sebastião AM, Ribeiro JA.

Curr Top Med Chem. 2011;11(8):1087-101. Review.

PMID:
21401493
11.

The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration.

O'Neill MJ, Murray TK, Lakics V, Visanji NP, Duty S.

Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):399-411. Review.

PMID:
12769612
12.
13.

The many roles of chemokine receptors in neurodegenerative disorders: emerging new therapeutical strategies.

Mines M, Ding Y, Fan GH.

Curr Med Chem. 2007;14(23):2456-70. Review.

PMID:
17979699
14.

Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.

Prediger RD.

J Alzheimers Dis. 2010;20 Suppl 1:S205-20. doi: 10.3233/JAD-2010-091459. Review.

PMID:
20182024
15.

Caffeine and adenosine.

Ribeiro JA, Sebastião AM.

J Alzheimers Dis. 2010;20 Suppl 1:S3-15. doi: 10.3233/JAD-2010-1379. Review.

PMID:
20164566
16.

Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.

Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N Jr, Chen JF.

Neurology. 2003 Dec 9;61(11 Suppl 6):S55-61. Review.

PMID:
14663012
17.

Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.

Ross GW, Petrovitch H.

Drugs Aging. 2001;18(11):797-806. Review.

PMID:
11772120
18.

Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.

Rivera-Oliver M, Díaz-Ríos M.

Life Sci. 2014 Apr 17;101(1-2):1-9. doi: 10.1016/j.lfs.2014.01.083. Epub 2014 Feb 13. Review.

19.

Adenosine receptor control of cognition in normal and disease.

Chen JF.

Int Rev Neurobiol. 2014;119:257-307. doi: 10.1016/B978-0-12-801022-8.00012-X. Review.

PMID:
25175970
20.

Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.

Schwarzschild MA, Chen JF, Ascherio A.

Neurology. 2002 Apr 23;58(8):1154-60. Review.

PMID:
11971080

Supplemental Content

Support Center